BRCA2 and breast carcinoma: The Talazoparib Beyond BRCA (TBB) trial included any solid tumor with germline or somatic mutations in HR-related genes other than BRCA1 and BRCA2 in cohort B. They reported a 31% overall response rate in breast cancer patients.